 The model includes the possibility of making 3 attempts in addition to the initial attempt to quit smoking, regardless of whether these were due to the failure of each attempt or due to relapse.
 Cost of reimbursement varenicline was estimated to be €17.1 million (€6.4 million corresponding to the drug), while smoking cessation avoided costs would be €27.7 million, which compared with €5.6 million savings in the not-reimbursed scenario: an incremental cost-saving of €5.5 million (Table 4 & Figure 2 ).
 Results were robust through several alternative scenarios including that of the Spanish NHS (Figure 3 ).
 Five-years cumulated cessation attempts increased from 26,468 in the not-reimbursed to 66,872 in the reimbursed scenario, yielding to 8,273 extra subjects quitting smoking (Tables 3 and 4) .
 We performed a BI analysis from the NHS perspective, with a 5-year horizon, of the funding of varenicline (Champix®) and nicotine replacement therapies (NRT) as treatment for smoking cessation in smokers either having previously suffered from Major Depressive Disorder (MDD) or who are stable and receiving antidepressant treatment.
 The BI analysis was performed using a hybrid model (smoker patients cohort and Markov chains for cessations attempts) that represents the smoker population with MDD that would attempt to quit smoking using drugs and medical follow-up in Spain during a 5-year period (Figure 1 ).
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